Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2020-04-16 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于2017年股票期权激励计划预留授予第一个行权期可行权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the exercise of stock options under the company's 2017 stock option incentive plan. It includes information about the number of options exercisable, the exercise price, the conditions met for exercising, approvals by the board and supervisory committee, legal opinions, and financial advisor opinions. The document is not a full financial report, earnings release, or management discussion but rather a formal announcement about stock option exercise rights and related corporate governance matters. It is not a report publication announcement since it contains substantive details and is longer than 5,000 characters. The content fits best under a regulatory announcement category related to capital structure changes and stock option exercises. According to the filing definitions, this corresponds to a Capital/Financing Update (CAP) as it updates on company financing activities and capital structure changes through stock option exercises.
2020-04-16 Chinese
2020年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020年第一季度报告全文" which translates to "2020 First Quarter Report Full Text." It contains detailed financial data including income statement, balance sheet, cash flow statement, and management commentary for the first quarter of 2020. The content includes comprehensive financial metrics, explanations of changes, shareholder information, and detailed financial statements. The length is substantial (15,000 characters) and it is not merely an announcement or a certification. The document is a quarterly financial report containing actual financial statements and substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-15 Chinese
关于2020年第一季度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (465 characters) about the upcoming disclosure of the company's 2020 first quarter report. It states that the 2020 first quarter report will be disclosed on a specific date and provides a link to the disclosure website. There is no actual financial data or detailed report content included in this document. According to the 'MENU VS MEAL' rule, this is an announcement about the report publication, not the report itself. Therefore, the correct classification is Report Publication Announcement (RPA).
2020-04-15 Chinese
关于对深圳证券交易所关注函的回复公告
Regulatory Filings Classification · 95% confidence The document is a detailed response from a company to a regulatory inquiry from the Shenzhen Stock Exchange regarding the rationale and details of a capital increase through stock dividend (转增股本). It includes extensive financial data, business growth analysis, dividend history, and internal procedures related to the profit distribution plan. The document is not a full annual or interim report but rather a regulatory reply to a specific inquiry about capital structure changes and dividend policy. It does not contain full financial statements or comprehensive financial performance disclosures typical of Annual Reports (10-K) or Interim Reports (IR). It is also not a simple announcement or certification but a substantive regulatory filing responding to an exchange's letter. Therefore, the best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2020-04-08 Chinese
2020年第一季度业绩预增公告
Earnings Release Classification · 95% confidence The document is a 2020 first quarter performance forecast announcement by the company, indicating expected net profit growth for the period January 1 to March 31, 2020. It explicitly states that the forecast is unaudited and preliminary, with detailed financial data to be disclosed in the official first quarter report later. The document is short (822 characters) and serves as a performance forecast rather than a full interim or quarterly report containing actual financial statements or substantive financial data. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. Q1 2020
2020-04-08 Chinese
2019年财务决算报告
Annual Report Classification · 95% confidence The document is titled as a 2019 financial settlement report for 健帆生物科技集团股份有限公司, containing detailed financial data such as revenue, net profit, assets, liabilities, cash flow, and financial ratios for the year ending December 31, 2019. It includes comprehensive financial statements and analysis of financial performance and position, typical of an annual report. The length of the document (7466 characters) and the detailed financial content confirm it is the full report, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2019
2020-04-01 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.